All In Biotech

Drug Trial Radar · NCT01757795

Safety, Tolerability and Pharmacokinetics of SP-8203

A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8203

Last checked: Nov 20, 2026Latest source record: Jul 22, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Dec 23, 2013

Primary completion

Mar 11, 2015

Study completion Mar 11, 2015

Sponsor

Sponsor type
Industry
First posted
Dec 31, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Phase I study in health volunteers to assess the safety, tolerability and pharmacokinetics of escalating single doses and multiple doses of SP-8203

Conditions

  • Ischemic Stroke

Interventions

  • SP-8203Drug

    SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial

  • PlaceboDrug

    Placebo will be intravenously administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence rate of adverse events, and adverse drug reaction in single ascending doses (SAD)Time frame: Follow-up to 7 days after administration
  2. The incidence rate of adverse events, and adverse drug reaction in multiple ascending doses (MAD)Time frame: Follow-up to 13 days after first administration
  3. Pharmacokinetics in single ascending doses (SAD)Time frame: within 3 days of administration
  4. Pharmacokinetics in multiple ascending doses (MAD)Time frame: within 9 days of first administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.